Mandal Surjyanarayan, Mandal Snigdha Das, Chuttani Krishna, Sawant Krutika K, Subudhi Bharat Bhushan
School of Pharmaceutical Sciences, Siksha 'O' Anusandhan University, Khandagiri Square, Bhubaneswar, Orissa, India.
Department of Pharmacology, Parul Institute of Pharmacy and Research, Vadodara, Gujarat, India.
Iran J Pharm Res. 2018 Winter;17(1):23-38.
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), showed very promising neuroprotection action, but it suffers from high first pass metabolism and limited ability to cross blood brain barrier. Severe gastric toxicity following oral administration further limits its utility. Hence, the aim of this study was to investigate whether ibuprofen loaded mucoadhesive microemulsion (MMEI) could enhance the brain uptake and could also protect the dopaminergic neurons from MPTP-mediated neural inflammation. In this work, ibuprofen loaded polycarbophil based mucoadhesive microemulsion (MMEI) was developed by using response surface methodology (RSM). Male C57BL/6 mice were intranasally given 2.86 mg ibuprofen/kg/day for 2 consecutive weeks, which were pre-treated with four MPTP injections (20 mg/kg of body weight) at 2 h interval by intraperitoneal route and immunohistochemistry was performed. Globule size of optimal MMEI was 46.73 nm ± 3.11 with PdI value as 0.201 ± 0.19. Histological observation showed that optimal MMEI was biocompatible and suitable for nasal application. The result showed very significant effect ( 0.05) of all three independent variables on the responses of the developed MMEI. Noticeable improvement in motor performance with spontaneous behavior was observed. TH neurons count in substantia nigra with the density of striatal dopaminergic nerve terminals after MMEI administration. Results of this study confirmed neuroprotection action of ibuprofen through intranasal MMEI against MPTP induced inflammation in dopaminergic nerves in animal model and hence, MMEI can be useful for prevention and management of Parkinson disease (PD).
布洛芬是一种非甾体抗炎药(NSAID),具有非常有前景的神经保护作用,但它存在首过代谢率高和穿越血脑屏障能力有限的问题。口服给药后严重的胃毒性进一步限制了其应用。因此,本研究的目的是探讨载布洛芬的黏膜黏附微乳剂(MMEI)是否能增强脑摄取,以及是否能保护多巴胺能神经元免受MPTP介导的神经炎症影响。在本研究中,采用响应面法(RSM)制备了载布洛芬的基于聚卡波非的黏膜黏附微乳剂(MMEI)。雄性C57BL/6小鼠连续2周经鼻给予2.86 mg/kg/天的布洛芬,这些小鼠通过腹腔途径每隔2小时预先注射4次MPTP(20 mg/kg体重),然后进行免疫组织化学检测。最佳MMEI的球粒大小为46.73 nm±3.11,多分散指数(PdI)值为0.201±0.19。组织学观察表明,最佳MMEI具有生物相容性,适合鼻腔给药。结果显示,所有三个自变量对所制备的MMEI的响应均具有非常显著的影响(P<0.05)。观察到运动性能和自发行为有明显改善。给予MMEI后,黑质中TH神经元计数及纹状体多巴胺能神经末梢密度增加。本研究结果证实,在动物模型中,经鼻给予MMEI,布洛芬对MPTP诱导的多巴胺能神经炎症具有神经保护作用,因此,MMEI可用于帕金森病(PD)的预防和治疗。